Vor-Wordmark-RGB-FullColor-070920.png
First AML Patient Successfully Transplanted with Vor Bio’s Investigational Trem-cel (VOR33) and Tolerated Mylotarg™
December 07, 2022 07:30 ET | Vor Biopharma
Trem-cel (formerly VOR33) successfully manufactured and engrafted normallyBlood counts successfully maintained following post-transplant treatment with MylotargConference call scheduled for today,...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio to Participate in Upcoming Investor Conferences
November 22, 2022 08:00 ET | Vor Biopharma
CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio Reports Third Quarter 2022 Financial Results and Provides Company Update
November 10, 2022 16:15 ET | Vor Biopharma
Initial clinical data for VOR33 on track for Q4 2022Eyal C. Attar, M.D. appointed as Chief Medical OfficerInitiated in-house clinical manufacturing at Cambridge, MA headquarters CAMBRIDGE, Mass.,...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio to Participate in Upcoming Investor Conferences
November 01, 2022 08:00 ET | Vor Biopharma
CAMBRIDGE, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio Appoints Eyal C. Attar, M.D. as Chief Medical Officer
October 12, 2022 08:00 ET | Vor Biopharma
CAMBRIDGE, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Eyal C. Attar, M.D., has joined Vor Bio as Chief...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio Demonstrates Potential of Base and Sequential Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment
October 11, 2022 08:00 ET | Vor Biopharma
-Multiplex deletion of myeloid antigens CD33 and CLL-1 or CD33 and CD123 in human hematopoietic stem cells resulted in long-term engraftment and persistence of editing -Data presented at European...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio Initiates In-house Clinical Manufacturing at Cambridge, MA Headquarters
September 28, 2022 08:00 ET | Vor Biopharma
CAMBRIDGE, Mass., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the opening of its new in-house clinical...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio to Participate in Upcoming Investor Conferences
September 06, 2022 16:15 ET | Vor Biopharma
CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio Reports Second Quarter 2022 Financial Results and Provides Company Update
August 11, 2022 16:15 ET | Vor Biopharma
Initial clinical data for patients treated with Vor Bio’s engineered HSC candidate VOR33 on track for Q4 2022In-house manufacturing facility in Cambridge, MA operational in Q4 2022Data presented at...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio to Participate in Upcoming Investor Conferences
August 01, 2022 08:00 ET | Vor Biopharma
CAMBRIDGE, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...